RecruitingNot ApplicableNCT06276634

Intermittent Hypoxia in Persons With Multiple Sclerosis

Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis

Sponsor

Shirley Ryan AbilityLab

Enrollment

21 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

Multiple Sclerosis

Summary

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether brief, controlled exposure to low-oxygen air (intermittent hypoxia — similar to being at high altitude) can improve movement and strength in people with relapsing forms of multiple sclerosis (MS). Researchers believe this may stimulate the nervous system to work better. **You may be eligible if...** - You have relapsing-remitting MS or secondary-progressive MS - Your disability level is moderate (EDSS score between 3 and 6.5) - You have been relapse-free for at least 1 year - You are between 18 and 75 years old - You are safe to have an MRI scan **You may NOT be eligible if...** - You have active MS lesions or recent stroke signs on MRI - You have uncontrolled high blood pressure - You have epilepsy, COPD, or uncontrolled sleep apnea - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAcute Intermittent Hypoxia

During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.

OTHERSham-Acute Intermittent Hypoxia

During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.

Locations(1)

Shirley Ryan AbilityLab

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06276634

Related Trials

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?

NCT053577811 location

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

NCT000012481 location

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

NCT027842101 location

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

NCT058494671 location

Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)

NCT067952301 location